Anthony D. Ho

Synergistic activity of nilotinib and established chemotherapeutic drugs in imatinib-sensitive and -resistant BCR-ABL-positive cells

A. Ho, W. Zeller, A. Radujkovic, 2010, Cancer Chemotherapy and Pharmacology.

Favorable therapeutic index of a p210BCR-ABL-specific tyrosine kinase inhibitor; activity on lineage-committed and primitive chronic myelogenous leukemia progenitors

A. Ho, E. Buchdunger, W. Zeller, 1999, Cancer Chemotherapy and Pharmacology.